

Datasheet: MCA6103

Description:	HUMAN ANTI C5 (ECULIZUMAB BIOSIMILAR)
Specificity:	C5
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	Eculizumab
Isotype:	IgG2 Kappa
Quantity:	0.2 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human
Product Form	Human IgG2/4 (kappa) antibody - liquid
Preparation	Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.02% Proclin 300
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	Human C5
External Database Links	<p>UniProt: P01031 Related reagents</p> <p>Entrez Gene: 727 C5 Related reagents</p>

Synonyms CPAMD4

Specificity **Human Anti-C5 Antibody** is a research grade biosimilar of the monoclonal antibody drug eculizumab. It is a recombinant human IgG2/4 kappa antibody with variable regions from the therapeutic antibody eculizumab.

Human Anti-C5 Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-eculizumab antibodies. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-eculizumab antibody in IgG1 format as reference standard.

Eculizumab (Soliris) is a humanized IgG2/4 kappa antibody. The heavy chains are comprised of human IgG2 sequences in CH1, the hinge and the adjacent portion CH2, and human IgG4 sequences in the remaining part of CH2 and CH3. The drug is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired life-threatening disease of the blood characterized by destruction of red blood cells by the complement system. It also has approval as an orphan drug for treatment of atypical hemolytic uremic syndrome (aHUS). Eculizumab specifically binds to the terminal complement component 5 (C5) and inhibits the cleavage of C5 to C5a and C5b by the C5 convertase, which prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. A 1:1 molar ratio of eculizumab to C5 is sufficient for C5 inhibition.

This product is NOT FOR THERAPEUTIC USE.

Purity >98% by SDS PAGE

Storage Store at +4°C or at -20°C if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee 12 months from date of despatch

Health And Safety Information Material Safety Datasheet documentation #20463 available at:
20463: <https://www.bio-rad-antibodies.com/uploads/MSDS/20463.pdf>

Licensed Use For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

Regulatory For research purposes only

Related Products

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

Printed on 27 Aug 2020

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)